Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 14, 2025, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2025 and provided a business update.</li><li>Following the release of promising Phase 2a clinical trial results for SGX945 (dusquetide) in Behcet's Disease, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to dusquetide for "treatment of Behcet's Disease".</li><li>The company has begun work on a subcutaneous formulation of SGX945, after which it is planning to perform a Phase 2b trial in Behcet's Disease.</li></ul>

On August 14, 2025, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2025 and provided a business update.Following the release of promising Phase 2a clinical trial results for SGX945 (dusquetide) in Behcet's Disease, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to dusquetide for "treatment of Behcet's Disease".The company has begun work on a subcutaneous formulation of SGX945, after which it is planning to perform a Phase 2b trial in Behcet's Disease.

SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet's Disease 